76.54
Schlusskurs vom Vortag:
$76.09
Offen:
$74.7
24-Stunden-Volumen:
97,369
Relative Volume:
0.06
Marktkapitalisierung:
$8.13B
Einnahmen:
$628.56M
Nettoeinkommen (Verlust:
$141.82M
KGV:
60.75
EPS:
1.26
Netto-Cashflow:
$142.60M
1W Leistung:
+1.97%
1M Leistung:
+10.52%
6M Leistung:
+33.06%
1J Leistung:
+175.00%
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Vergleichen Sie CORT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CORT
Corcept Therapeutics Inc
|
76.65 | 7.78B | 628.56M | 141.82M | 142.60M | 1.26 |
![]()
ONC
Beigene Ltd Adr
|
241.70 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
432.08 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.04 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.45 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-06 | Hochstufung | Truist | Hold → Buy |
2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
2022-08-01 | Herabstufung | Truist | Buy → Hold |
2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
2022-01-28 | Eingeleitet | Truist | Buy |
2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
2019-09-24 | Eingeleitet | Jefferies | Buy |
2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
2018-08-10 | Bestätigt | Stifel | Hold |
2018-05-31 | Herabstufung | Stifel | Buy → Hold |
2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
2017-08-31 | Eingeleitet | Stifel | Buy |
2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
2015-04-21 | Eingeleitet | FBR Capital | Outperform |
2014-01-13 | Herabstufung | Stifel | Buy → Hold |
2013-08-09 | Herabstufung | Janney | Buy → Neutral |
2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent
Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance
Critical Review: Kaya (OTCMKTS:KAYS) vs. Corcept Therapeutics (NASDAQ:CORT) - Defense World
Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight - Yahoo Finance
Cushing's Syndrome Market Growth Drivers and Industry Insights - openPR.com
Corcept Therapeutics (NASDAQ:CORT) Downgraded to “Hold” Rating by StockNews.com - Defense World
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There - Yahoo Finance
Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now - Insider Monkey
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call - ACCESS Newswire
HC Wainwright Has Pessimistic Outlook of CORT Q2 Earnings - Defense World
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $143.25 - Defense World
Corcept Therapeutics chief development officer sells $524,652 in stock By Investing.com - Investing.com India
Corcept Therapeutics chief development officer sells $524,652 in stock - Investing.com Australia
Insider Sell: William Guyer Sells Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World
Corcept Therapeutics (NASDAQ:CORT) Raised to Buy at StockNews.com - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2025 Earnings Call Transcript - Insider Monkey
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall - MSN
Corcept Therapeutics price target lowered to $135 from $150 at Truist - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Down on Insider Selling - Defense World
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS - Yahoo Finance
Corcept Therapeutics (CORT) Faces Price Target Cut Amid Revenue Concerns | CORT Stock News - GuruFocus
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts - Benzinga
Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating - marketscreener.com
H.C. Wainwright cuts Corcept Therapeutics target to $145 By Investing.com - Investing.com Nigeria
Corcept Therapeutics (CORT) Receives Revised Price Target from A - GuruFocus
Corcept Therapeutics (CORT) Receives Revised Price Target from Analyst | CORT Stock News - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Pr - GuruFocus
Corcept Therapeutics (CORT) Maintains Buy Rating Amid Revised Price Target | CORT Stock News - GuruFocus
Corcept Therapeutics Inc Q1 2025 Earnings: EPS of $0.17 Beats Es - GuruFocus
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS A - GuruFocus
Corcept Therapeutics (CORT) Pre-Earnings Options Activity Sugges - GuruFocus
Corcept Therapeutics (CORT) Anticipates Future Growth Amid Reven - GuruFocus
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges - GuruFocus
Decoding Corcept Therapeutics Inc (CORT): A Strategic SWOT Insig - GuruFocus
Corcept Therapeutics Reports Q1 2025 Financial Results - TipRanks
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars - MSN
Corcept: Q1 Earnings Snapshot - MySA
Corcept Therapeutics (CORT) Set to Announce Q1 Earnings - GuruFocus
Earnings call transcript: Corcept Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com UK
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates - Yahoo Finance
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops - Yahoo Finance
Corcept Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CORCEPT THERAPEUTICS Earnings Results: $CORT Reports Quarterly Earnings - Nasdaq
Corcept Therapeutics Q1 Earnings Decrease, Revenue Rises -- Shares Fall After Hours - marketscreener.com
Corcept Therapeutics (CORT) Reports Q1 Revenue Miss | CORT Stock News - GuruFocus
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):